EMA Authorised: Dapagliflozin Viatris (dapagliflozin) — Viatris Limited

View source ↗

Summary

EMA authorised Dapagliflozin Viatris for type 2 diabetes mellitus, heart failure, and chronic kidney disease, with Viatris Limited as the marketing authorisatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure
• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin Viatris (dapagliflozin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2;Heart Failure, Systolic;Heart Failure;Renal Insufficiency, Chronic. MAH: Viatris Limited. Decision date: 23/01/2026